Association of epidermal growth factor receptor (EGFR) gene polymorphism with lung cancer risk: a systematic review

2014 ◽  
Vol 34 (5) ◽  
pp. 333-334 ◽  
Author(s):  
Xu Feng ◽  
Jia-Jin Qin ◽  
Bao-Shi Zheng ◽  
Liu-Liu Huang ◽  
Xiao-Yong Xie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Gene Polymorphism ◽  
Lung Cancer Risk ◽  
Growth Factor Receptor ◽  
Egfr Gene ◽  
Epidermal Growth

scholarly journals The Association between Epidermal Growth Factor Receptor (EGFR) Gene Polymorphisms and Lung Cancer Risk

Biomolecules ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. 53 ◽  
Author(s):  
Nabil Bashir ◽  
Entesar Ragab ◽  
Omar Khabour ◽  
Basheer Khassawneh ◽  
Mahmoud Alfaqih ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Risk ◽  
Gene Polymorphisms ◽  
Lung Cancer Risk ◽  
Growth Factor Receptor ◽  
Egfr Gene ◽  
Epidermal Growth

Lung cancer is the leading cause of cancer death globally. The epidermal growth factor receptor (EGFR) plays an important role in cell proliferation and signaling. In this study, we examined the association between EGFR gene polymorphisms and lung cancer risk among the Jordanian population. A total of 129 patients with primary lung cancer and 129 matched healthy controls were recruited into this study. EGFR rs712829, rs712830, rs2072454, and rs11543848 single nucleotide polymorphisms (SNPs) were genotyped to test for their association with lung cancer risk. A significant association was observed between the rs712829 SNP and lung cancer risk (p < 0.05) where the GG + GT genotypes were higher in lung cancer patients when compared to controls. In addition, no association was detected between rs712830, rs2072454, and rs11543848 SNPs and lung cancer risk. When patients were stratified according to the lung cancer type, a significant association was detected between both rs712829 and rs2072454 and adenocarcinoma lung cancer (p < 0.05). Haplotype analysis of all four SNPs showed a significant association between the TCCG haplotype and both lung cancer and the adenocarcinoma subtype (p < 0.001). In conclusion, EGFR rs712829, rs2072454 SNPs, and TCCG haplotypes are associated with a risk of lung cancer among Jordanians. Since genetic associations are affected by the genetic background of populations, more studies in other Arab populations are required to confirm the present findings.

scholarly journals The Association between Epidermal Growth Factor Receptor (EGFR) Gene Polymorphisms and Lung Cancer Risk

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Nabil Bashir ◽  
Entesar Ragab ◽  
Omar Khabour ◽  
Mahmoud Alfaqih ◽  
Basheer Khassawneh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Risk ◽  
Gene Polymorphisms ◽  
Lung Cancer Risk ◽  
Growth Factor Receptor ◽  
Egfr Gene ◽  
Epidermal Growth

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

2005 ◽  
Vol 23 (11) ◽  
pp. 2513-2520 ◽  
Author(s):  
Tetsuya Mitsudomi ◽  
Takayuki Kosaka ◽  
Hideki Endoh ◽  
Yoshitsugu Horio ◽  
Toyoaki Hida ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Egfr Mutations ◽  
Egfr Gene ◽  
Serum Carcinoembryonic Antigen ◽  
Gefitinib Treatment ◽  
Epidermal Growth

Purpose To evaluate the relationship between mutations of the epidermal growth factor receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent lung cancer after pulmonary resection. Patients and Methods We sequenced exons 18-21 of the EGFR gene using total RNA extracted from 59 patients with lung cancer who were treated with gefitinib for recurrent lung cancer. Gefitinib effectiveness was evaluated by both imaging studies and change in serum carcinoembryonic antigen (CEA) levels. Results EGFR mutations were found in 33 patients (56%). Of these mutations, 17 were deletions around codons 746-750 and 15 were point mutations (12 at codon 858, three at other codons), and one was an insertion. EGFR mutations were significantly more prevalent in females, adenocarcinoma, and never-smokers. Gefitinib treatment resulted in tumor shrinkage and/or CEA decrease to less than half of the baseline level in 26 patients, tumor growth and/or CEA elevation in 24 patients, and gefitinib effect was not assessable in nine patients. Female, never-smoking patients with adenocarcinoma tended to respond better to gefitinib treatment. Gefitinib was effective in 24 of 29 patients with EGFR mutations, compared with two of 21 patients without mutations (P < .0001). Of note, del746-750 might be superior to L858R mutations for prediction of gefitinib response. Patients with EGFR mutations survived for a longer period than those without the mutations after initiation of gefitinib treatment (P = .0053). Conclusion EGFR mutations were a good predictor of clinical benefit of gefitinib in this setting.

Sign in / Sign up

Export Citation Format

Share Document